Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
Identifieur interne : 000963 ( Main/Exploration ); précédent : 000962; suivant : 000964Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
Auteurs : Keith Copelin Ferdinand [États-Unis] ; Uri Elkayam [États-Unis] ; Donna Mancini [États-Unis] ; Elizabeth Ofili [Géorgie (pays)] ; Ileana Pi A [États-Unis] ; Inder Anand [États-Unis] ; Arthur Michael Feldman [États-Unis] ; Dennis Mcnamara [États-Unis] ; Christopher Leggett [Géorgie (pays)]Source :
- The American journal of cardiology [ 1879-1913 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- mortalité : Défaillance cardiaque.
- traitement médicamenteux : Défaillance cardiaque.
- usage thérapeutique : Dinitrate isosorbide, Hydralazine.
- Afro-Américains, Association médicamenteuse, Guides de bonnes pratiques cliniques comme sujet, Humains.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Hydralazine, Isosorbide Dinitrate.
- chemical : Drug Combinations.
- drug therapy : Heart Failure.
- mortality : Heart Failure.
- African Americans, Humans, Practice Guidelines as Topic.
Abstract
The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A). Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine may mitigate nitrate tolerance, and the ISDN-hydralazine combination in the Vasodilators in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identified black participants. In the subsequent V-HeFT II, survival was greater with enalapril than with ISDN-hydralazine in the overall cohort, but mortality rate was similar in the enalapril and ISDN-hydralazine groups in the self-identified black patients. Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT and its substudies demonstrated not only improvements in echocardiographic parameters, morbidity, and mortality but also a decrease in hospitalizations, potentially affecting burgeoning HF health-care costs. Genetic characteristics may, therefore, determine response to ISDN-hydralazine, and the Genetic Risk Assessment in Heart Failure substudy demonstrated important hypothesis-generating pharmacogenetic data.
DOI: 10.1016/j.amjcard.2014.04.018
PubMed: 24846808
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002482
- to stream PubMed, to step Curation: 002472
- to stream PubMed, to step Checkpoint: 002472
- to stream Ncbi, to step Merge: 002135
- to stream Ncbi, to step Curation: 002135
- to stream Ncbi, to step Checkpoint: 002135
- to stream Main, to step Merge: 000968
- to stream Main, to step Curation: 000963
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.</title><author><name sortKey="Ferdinand, Keith Copelin" sort="Ferdinand, Keith Copelin" uniqKey="Ferdinand K" first="Keith Copelin" last="Ferdinand">Keith Copelin Ferdinand</name><affiliation wicri:level="2"><nlm:affiliation>Tulane University School of Medicine, New Orleans, Louisiana. Electronic address: kferdina@tulane.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Tulane University School of Medicine, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Elkayam, Uri" sort="Elkayam, Uri" uniqKey="Elkayam U" first="Uri" last="Elkayam">Uri Elkayam</name><affiliation wicri:level="2"><nlm:affiliation>University of Southern California Keck School of Medicine, Los Angeles, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>University of Southern California Keck School of Medicine, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Mancini, Donna" sort="Mancini, Donna" uniqKey="Mancini D" first="Donna" last="Mancini">Donna Mancini</name><affiliation wicri:level="2"><nlm:affiliation>Columbia University College of Physicians and Surgeons, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Columbia University College of Physicians and Surgeons, New York</wicri:cityArea></affiliation></author><author><name sortKey="Ofili, Elizabeth" sort="Ofili, Elizabeth" uniqKey="Ofili E" first="Elizabeth" last="Ofili">Elizabeth Ofili</name><affiliation wicri:level="1"><nlm:affiliation>Morehouse School of Medicine, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Morehouse School of Medicine, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Pi A, Ileana" sort="Pi A, Ileana" uniqKey="Pi A I" first="Ileana" last="Pi A">Ileana Pi A</name><affiliation wicri:level="2"><nlm:affiliation>Montefiore Einstein Center for Heart and Vascular Care, Bronx, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Montefiore Einstein Center for Heart and Vascular Care, Bronx</wicri:cityArea></affiliation></author><author><name sortKey="Anand, Inder" sort="Anand, Inder" uniqKey="Anand I" first="Inder" last="Anand">Inder Anand</name><affiliation wicri:level="2"><nlm:affiliation>Minneapolis VA Medical Center, Minneapolis, Minnesota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Minneapolis VA Medical Center, Minneapolis</wicri:cityArea></affiliation></author><author><name sortKey="Feldman, Arthur Michael" sort="Feldman, Arthur Michael" uniqKey="Feldman A" first="Arthur Michael" last="Feldman">Arthur Michael Feldman</name><affiliation wicri:level="2"><nlm:affiliation>Temple University Health System, Philadelphia, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Temple University Health System, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Mcnamara, Dennis" sort="Mcnamara, Dennis" uniqKey="Mcnamara D" first="Dennis" last="Mcnamara">Dennis Mcnamara</name><affiliation wicri:level="2"><nlm:affiliation>University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>University of Pittsburgh School of Medicine, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Leggett, Christopher" sort="Leggett, Christopher" uniqKey="Leggett C" first="Christopher" last="Leggett">Christopher Leggett</name><affiliation wicri:level="1"><nlm:affiliation>East Georgia Regional Medical Center, Statesboro, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>East Georgia Regional Medical Center, Statesboro</wicri:regionArea><wicri:noRegion>Statesboro</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24846808</idno><idno type="pmid">24846808</idno><idno type="doi">10.1016/j.amjcard.2014.04.018</idno><idno type="wicri:Area/PubMed/Corpus">002482</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002482</idno><idno type="wicri:Area/PubMed/Curation">002472</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002472</idno><idno type="wicri:Area/PubMed/Checkpoint">002472</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002472</idno><idno type="wicri:Area/Ncbi/Merge">002135</idno><idno type="wicri:Area/Ncbi/Curation">002135</idno><idno type="wicri:Area/Ncbi/Checkpoint">002135</idno><idno type="wicri:Area/Main/Merge">000968</idno><idno type="wicri:Area/Main/Curation">000963</idno><idno type="wicri:Area/Main/Exploration">000963</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.</title><author><name sortKey="Ferdinand, Keith Copelin" sort="Ferdinand, Keith Copelin" uniqKey="Ferdinand K" first="Keith Copelin" last="Ferdinand">Keith Copelin Ferdinand</name><affiliation wicri:level="2"><nlm:affiliation>Tulane University School of Medicine, New Orleans, Louisiana. Electronic address: kferdina@tulane.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Tulane University School of Medicine, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Elkayam, Uri" sort="Elkayam, Uri" uniqKey="Elkayam U" first="Uri" last="Elkayam">Uri Elkayam</name><affiliation wicri:level="2"><nlm:affiliation>University of Southern California Keck School of Medicine, Los Angeles, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>University of Southern California Keck School of Medicine, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Mancini, Donna" sort="Mancini, Donna" uniqKey="Mancini D" first="Donna" last="Mancini">Donna Mancini</name><affiliation wicri:level="2"><nlm:affiliation>Columbia University College of Physicians and Surgeons, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Columbia University College of Physicians and Surgeons, New York</wicri:cityArea></affiliation></author><author><name sortKey="Ofili, Elizabeth" sort="Ofili, Elizabeth" uniqKey="Ofili E" first="Elizabeth" last="Ofili">Elizabeth Ofili</name><affiliation wicri:level="1"><nlm:affiliation>Morehouse School of Medicine, Atlanta, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>Morehouse School of Medicine, Atlanta</wicri:regionArea><wicri:noRegion>Atlanta</wicri:noRegion></affiliation></author><author><name sortKey="Pi A, Ileana" sort="Pi A, Ileana" uniqKey="Pi A I" first="Ileana" last="Pi A">Ileana Pi A</name><affiliation wicri:level="2"><nlm:affiliation>Montefiore Einstein Center for Heart and Vascular Care, Bronx, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Montefiore Einstein Center for Heart and Vascular Care, Bronx</wicri:cityArea></affiliation></author><author><name sortKey="Anand, Inder" sort="Anand, Inder" uniqKey="Anand I" first="Inder" last="Anand">Inder Anand</name><affiliation wicri:level="2"><nlm:affiliation>Minneapolis VA Medical Center, Minneapolis, Minnesota.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Minneapolis VA Medical Center, Minneapolis</wicri:cityArea></affiliation></author><author><name sortKey="Feldman, Arthur Michael" sort="Feldman, Arthur Michael" uniqKey="Feldman A" first="Arthur Michael" last="Feldman">Arthur Michael Feldman</name><affiliation wicri:level="2"><nlm:affiliation>Temple University Health System, Philadelphia, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Temple University Health System, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Mcnamara, Dennis" sort="Mcnamara, Dennis" uniqKey="Mcnamara D" first="Dennis" last="Mcnamara">Dennis Mcnamara</name><affiliation wicri:level="2"><nlm:affiliation>University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>University of Pittsburgh School of Medicine, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Leggett, Christopher" sort="Leggett, Christopher" uniqKey="Leggett C" first="Christopher" last="Leggett">Christopher Leggett</name><affiliation wicri:level="1"><nlm:affiliation>East Georgia Regional Medical Center, Statesboro, Georgia.</nlm:affiliation><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>East Georgia Regional Medical Center, Statesboro</wicri:regionArea><wicri:noRegion>Statesboro</wicri:noRegion></affiliation></author></analytic><series><title level="j">The American journal of cardiology</title><idno type="eISSN">1879-1913</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>African Americans</term><term>Drug Combinations</term><term>Heart Failure (drug therapy)</term><term>Heart Failure (mortality)</term><term>Humans</term><term>Hydralazine (therapeutic use)</term><term>Isosorbide Dinitrate (therapeutic use)</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afro-Américains</term><term>Association médicamenteuse</term><term>Dinitrate isosorbide (usage thérapeutique)</term><term>Défaillance cardiaque (mortalité)</term><term>Défaillance cardiaque (traitement médicamenteux)</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Hydralazine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hydralazine</term><term>Isosorbide Dinitrate</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Combinations</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Heart Failure</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Heart Failure</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Défaillance cardiaque</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Défaillance cardiaque</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Dinitrate isosorbide</term><term>Hydralazine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>African Americans</term><term>Humans</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Afro-Américains</term><term>Association médicamenteuse</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I, level A). Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine may mitigate nitrate tolerance, and the ISDN-hydralazine combination in the Vasodilators in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identified black participants. In the subsequent V-HeFT II, survival was greater with enalapril than with ISDN-hydralazine in the overall cohort, but mortality rate was similar in the enalapril and ISDN-hydralazine groups in the self-identified black patients. Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT and its substudies demonstrated not only improvements in echocardiographic parameters, morbidity, and mortality but also a decrease in hospitalizations, potentially affecting burgeoning HF health-care costs. Genetic characteristics may, therefore, determine response to ISDN-hydralazine, and the Genetic Risk Assessment in Heart Failure substudy demonstrated important hypothesis-generating pharmacogenetic data.</div></front></TEI><affiliations><list><country><li>Géorgie (pays)</li><li>États-Unis</li></country><region><li>Californie</li><li>Louisiane</li><li>Minnesota</li><li>Pennsylvanie</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Louisiane"><name sortKey="Ferdinand, Keith Copelin" sort="Ferdinand, Keith Copelin" uniqKey="Ferdinand K" first="Keith Copelin" last="Ferdinand">Keith Copelin Ferdinand</name></region><name sortKey="Anand, Inder" sort="Anand, Inder" uniqKey="Anand I" first="Inder" last="Anand">Inder Anand</name><name sortKey="Elkayam, Uri" sort="Elkayam, Uri" uniqKey="Elkayam U" first="Uri" last="Elkayam">Uri Elkayam</name><name sortKey="Feldman, Arthur Michael" sort="Feldman, Arthur Michael" uniqKey="Feldman A" first="Arthur Michael" last="Feldman">Arthur Michael Feldman</name><name sortKey="Mancini, Donna" sort="Mancini, Donna" uniqKey="Mancini D" first="Donna" last="Mancini">Donna Mancini</name><name sortKey="Mcnamara, Dennis" sort="Mcnamara, Dennis" uniqKey="Mcnamara D" first="Dennis" last="Mcnamara">Dennis Mcnamara</name><name sortKey="Pi A, Ileana" sort="Pi A, Ileana" uniqKey="Pi A I" first="Ileana" last="Pi A">Ileana Pi A</name></country><country name="Géorgie (pays)"><noRegion><name sortKey="Ofili, Elizabeth" sort="Ofili, Elizabeth" uniqKey="Ofili E" first="Elizabeth" last="Ofili">Elizabeth Ofili</name></noRegion><name sortKey="Leggett, Christopher" sort="Leggett, Christopher" uniqKey="Leggett C" first="Christopher" last="Leggett">Christopher Leggett</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000963 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000963 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24846808
|texte= Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24846808" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |